What impact is the Delta Variant of COVD-19 having on NAFLD and NASH? Let us count the ways in this lively, fast-paced episode with Donna Cryer and the Surfers:
16:11 – Global Liver Institute’s efforts to drive priority vaccine position for transplant and severely immunocompromised liver patients
22:12 – Creating the GLI Patient Insight and Data Center
28:26 – Relevance and importance of post-vaccine immunology testing in immunocompromised liver patients
33:11 – Perspectives from comparing UK and Israel data and studying the UK experience more generally
41:51 – The importance and limits of impact from FDA’s full approval of the Pfizer-BioNTech vaccine
47:42 – Why Global vaccine equity is so important to the future of the pandemic
50:20 – How experience with COVID-19 has improved clinical trial processes and procedures
54:30 – How much will Delta and future variants slow the rate of clinical trial progress?
TOPICS: Astra Zeneca, cirrhosis, COVID-19, Diagnostic Tests, education, Global Liver Institute, NAFLD, NASH, non-invasive liver testing, Obesity, vaccines, Pfizer, BioNTech, ,Moderna, vaccine hesitancy, immunocompromised patients
Surfing The NASH Tsunami is brought to you by HEP Dynamics
#HEPdynamics #SurfingNASH #podcast
